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Abstract
Background: Polycomb repressive complex 2 (PRC2; formed by EZH2, SUZ12, and EED protein subunits) and PRC1
(BMI1 protein) induce gene silencing through histone modification by H3K27me3. In the present study, we
characterized the PRC expression pattern and its clinical implication in sarcoma.
Methods: Using immunohistochemistry, we analyzed PRC expression in 105 sarcoma patients with 5 subtypes:
synovial sarcoma (n = 18), rhabdomyosarcoma (n = 28), Ewing sarcoma (n = 15), osteosarcoma (n = 30), and
others (n = 14).
Results: The median age at diagnosis in the patient cohort was 26.8 years (range: 1–78 years) and the male-to-female
ratio was 1:4. Initial disease presentation was locoregional disease in 83% of patients and initial metastatic disease in
the remaining 17%. PRC expression was not significantly different according to histologic subtype (P = 0.400). Overall
survival (OS) was significantly poor for SUZ12 high (P = 0.001), EED1 high (P = 0.279), and H3K27me3 high (P = 0.009).
Ultimately, patients with PRC2high had significantly inferior OS than the no expression group (P = 0.009). In the Cox
proportional hazard model adjusted for stage, histologic grade, surgery, margin and initial metastasis, SUZ12 expression
(P = 0.020, HR 29.069, 95% CI 1.690–500.007), H3K27me3 (P = 0.010, HR 3.743, 95% CI 1.370–10.228) expression was
significantly associated with shorter OS.
Conclusion: We detected PRC expression in various sarcomas and demonstrated its independent negative prognostic
role, suggesting the PRC axis as promising therapeutic target for treating sarcoma.
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Background
Sarcomas are a rare and highly heterogeneous group of
neoplasms originating from bone and soft tissue and
account for < 1% of all human malignancies [1, 2].
Although surgical resection is the primary treatment for
localized disease, more than 40% of cases ultimately
experience tumor recurrence, resulting in < 12 months
of overall survival (OS) [3]. For patients with these
tumors, mortality is high and the local and/or systemic
tumor burden results in significant morbidity.
Gene silencing though histone deacetylation, histone
methylation, and DNA methylation by deregulated
histone deacetylase (HDAC), histone methyltransferase,
and DNA methyltransferase has been widely investigated
in oncology studies. Among them, polycomb group
(PcG) proteins, as epigenetic chromatic modifiers,
exhibit histone methyltransferase activity. These proteins
regulate various physiologic processes, such as cell cycle,
embryogenic development, genetic imprinting, and
oncogenesis. The polycomb group protein consists of
multiprotein complexes, including polycomb repressive
complexes (PRC1) involved in the maintenance of gene
* Correspondence: hyosong77@yuhs.ac
†Equal contributors
9Division of Medical Oncology, Department of Internal Medicine, Yonsei
University College of Medicine, 134 Shinchondong, Seodaemun-gu, Seoul
120-752, South Korea
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cho et al. BMC Cancer  (2018) 18:158 
https://doi.org/10.1186/s12885-018-4066-6
silencing and PRC2, which initiates gene silencing.
PRC2, containing the enhancer of zeste homologue 2
(EZH2), induces histone H3 trimethylation at lysine 27
(H3K27me3) through histone methyltransferase activity.
PRC1, which contains BMI-1 (B lymphoma Mo-MLV
insertion region 1 homolog), is recruited to DNA by
binding to the H3K27me3 mark and mediates the ubi-
quitylation of histone 2A at lysine 119. Such coordinated
action of PRC2 and PRC1 associated with H3K27me3
on chromatin results in transcriptional repression [4].
The clinical relevance of PRC protein expression has
been studied in various solid tumors, such as colorectal
cancer, stomach cancer, and lymphoma [5–7]. However,
PRC expression and its clinical implications in sarcoma
have not been widely investigated.
In this study, we investigated PRC expression in
various subtypes of sarcoma and evaluated its clinical
relevance. We then analyzed the prognostic potential to
provide a practical guide as a diagnostic and therapeutic
strategy.
Methods
Patients and tissue samples
This study was conducted in a consecutive cohort of pa-
tients who were pathologically diagnosed with synovial
sarcoma, rhabdomyosarcoma, Ewing sarcoma, osteosar-
coma, mesenchymal chondrosarcoma, and epithelioid
sarcoma between 1994 and 2013 at the Yonsei Cancer
Center. A total of 105 formalin-fixed, paraffin-embedded
(FFPE) tissue blocks were available for examination of
PRC expression. Fortunately, the samples obtained are
all origin site specimens and the adjuvant therapy was
not previously performed. All hematoxylin and eosin
(H&E) slides were independently reviewed by two expe-
rienced pathologists (E.K.K. and S.H.K).
Clinicopathologic variables such as sex, age, tumor
histology and grade, tumor location, tumor stage, initial
presentation of disease, and status of the resection
margin were reviewed retrospectively from electronic
medical records. Tumors were graded according to the
FNCLCC (French Federation Nationale des Centre de
Lutte Contre le Cancer) [8]. Staging was determined
using the 7th edition American Joint Committee on
Cancer guideline of tumor, node, and metastasis (TNM)
classification. The study was approved by the institu-
tional review board of Severance Hospital.
Immunohistochemical staining and assessment
Tissue microarray blocks were prepared as follows: the
hematoxylin-eosin slides were reviewed and representa-
tive formalin-fixed, paraffin-embedded (FFPE) archival
blocks were selected for each case. Tumors were con-
firmed and marked on the slides under a microscope.
Two or three different representative tumor areas per
case were selected and used to prepare the tissue micro-
arrays. Core tissue biopsies (3 mm in diameter) were
taken from individual FFPE blocks (donor blocks) and
arranged in recipient paraffin blocks (tissue array blocks)
using a trephine apparatus. All tissue microarray blocks
were confirmed to contain suitable sarcoma lesions with
more than 50% of the core area after hematoxylin and
eosin staining. The original H&E slides were reviewed by
two pathologists (E.K.K and S.H.K).
Immunohistochemistry (IHC) staining for EZH2,
SUZ12, EED1, and H3K27me3 was performed on the
tissue microarray blocks using a standard protocol with
a Ventana automatic immunostainer (Ventana, Bench-
mark, Tuscan, AZ, USA) [9]. The primary antibodies
used in this study were as follows: EZH2 (#18–7395, di-
lution 1:100, clone ZMD.309; Invitrogen, Carlsbad, CA,
USA), SUZ12 (dilution 1:50, clone SUZ220A, Abcam,
Cambridge, MA, USA), EED1 (dilution 1:100, clone
163C, Abcam), H3K27me3 (dilution 1:100, clone
C36B11; Cell Signaling Technology, Danvers, MA,
USA). After deparaffinization, heat-induced antigen re-
trieval was performed using citrate buffer (CC1 protocol;
Ventana) at pH 6.0. Reactivity was detected using the
Ultra-View detection kit (Ventana). Positivity for each
marker was determined and scored independently by
two pathologists (E.K.K and S.H.K.). The percentage and
intensity of positive tumor cells were recorded by
manually counting representative fields of each case.
EZH2, SUZ12, EED1, and H3K27me3 showed nuclear
expression. For EZH2, SUZ12, EED1, and H3K27me3,
staining intensity (0, none to weak; 1, moderate to
strong) and the proportion of positive tumor cell nuclei
(0, < 10%; 1, ≥ 10 and < 75%; 2, ≥ 75%) were semi-
quantitatively graded as described. Based on the staining
intensity multiplied by the proportion of positive nuclei,
protein expression was scored as low (0), intermediate (1),
or high (2). The cutoff value for high expression was set as
a score of 2. [7] High PRC2 expression was defined as
cases that were positive for all PRC2 proteins (EZH2,
SUZ12, and EED1).
Statistical methods
SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA) was
used for statistical analyses. The correlation between
PRC expression and clinicopathologic variables was ana-
lyzed using independent sample t-test for continuous
variables and chi-square test for discrete variables. For
survival analysis, OS was defined as the time interval be-
tween the diagnosis of metastatic/recurrent disease and
death or last follow-up. Survival analysis was performed
using the Kaplan-Meier method with the log-rank test.
Multivariate analyses for overall survival were performed
using the Cox proportional hazards model. The accepted
level of statistical significance was P < 0.05.
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Result
Patient characteristics
Baseline clinicopathologic characteristics of the patients
are summarized in Table 1. Among the total of 105
cases, 62 were male (59.0%) with a median age at the
time of diagnosis of 26.8 years (range 1–78). Histologic
subtypes were as follows: osteosarcoma (n = 30, 29%),
followed by rhabdomyosarcoma (n = 28, 27%), synovial
sarcoma (n = 18, 17%), and Ewing sarcoma (n = 15, 14%).
Most cases were grade 3 (n = 99, 95%) and more than
one-third were located in the lower extremities (n = 44,
42%). Most patients had no distant metastasis at the
time of diagnosis (83%) and underwent surgical resec-
tion (n = 99, 95%). Adjuvant chemotherapy was given in
63 patients (65%), and 38 of these (40%) received con-
current radiotherapy.
PRC expression status and clinicopathologic features
For PRC2 (EZH2, SUZ12, and EED1 protein subunits)
and H3K27me3, representative images of PRC-positive
and PRC-negative cases are shown in Fig. 1. In Fig. 1. a-b,
c-d, e-f and g-h are combinations of samples showing the
high and low expression of the same polycomb proteins in
the same pathologies. In detail, the pleomorphic tumor
cells produce osteoid describing irregular trabeculae in
Fig. 1a. The specimen obtained from the patient diagnosed
with osteosarcoma has high grade expression of EZH2
staining. Fig. 1b. shows the specimen obtained from
patients diagnosed with osteosarcoma with low grade
expression of EZH2. c-d, e-f and g-h were diagnosed as
osteosarcoma but showed high grade and low grade
expression in SUZ12, EED1 and H3K27me3 expression,
respectively. The high expression rates of EZH2, SUZ12,
Table 1 Baseline characteristics
Variables All PRC2 expression P value
N (%) Low or Intermediate High
Sex Male 62 (59%) 59 (56%) 3 (3%) 0.965
Female 43 (41%) 41 (39%) 2 (2%)
Age at diagnosis (year, median, range) 26.8 (1–78) 26.3 ± 18.7 35.6 ± 19.7 0.280
Diagnosis Synovial sarcoma 18 (17%) 18 (17%) 0 (0%) 0.400
Rhabdomyosarcoma 28 (27%) 25 (24%) 3 (3%)
Ewing sarcoma 15 (14%) 14 (13%) 1 (1%)
Osteosarcoma 30 (29%) 29 (28%) 1 (1%)
Others 14 (13%) 14 (13%) 0 (0%)
Primary Site Head/Neck 20 (19%) 20 (19%) 0 (0%) 0.512
Trunk 29 (28%) 27 (26%) 2 (2%)
Upper Extremity 12 (11%) 12 (11%) 0 (0%)
Lower Extremity 44 (42%) 41 (39%) 3 (3%)
Histologic Grade Grade 1 4 (4%) 4 (4%) 0 (0%) 0.853
Grade 2 2 (2%) 2 (2%) 0 (0%)
Grade 3 99 (95%) 94 (90%) 5 (5%)
Initial distant metastasis No 83 (83%) 80 (80%) 3 (3%) 0.531
Yes 17 (17%) 16 (16%) 1 (1%)
Surgery No 6 (6%) 5 (5%) 1 (1%) 0.259
Yes 99 (95%) 95 (91%) 4 (4%)
Resection margin R0 68 (69%) 66 (67%) 2 (2%) 0.636
R1 29 (29%) 27 (27%) 2 (2%)
R2 2 (2%) 2 (2%) 0 (0%)
Stage I or II 53 (50%) 52 (49%) 1 (1%) 0.205
III or IV 52 (50%) 48 (46%) 4 (4%)
Chemotherapy No 33 (35%) 30 (31%) 3 (4%) 0.081
Yes 63 (65%) 62 (64%) 1 (1%)
Radiotherapy No 57 (60%) 56 (59%) 1 (1%) 0.144
Yes 38 (40%) 35 (37%) 3 (3%)
Cho et al. BMC Cancer  (2018) 18:158 Page 3 of 8
and EED1 were 77.1% (n = 81), 5.7% (n = 6), and
77.1% (n = 81), respectively. Each PRC expression level
was significantly different according to the histologic
subtype of sarcoma (Fig. 2). As seen in Fig. 2a,
SUZ12 and H3K27me3 are relatively low. Fig. 2b.
shows that EZH2 and H3K27me3 are low at the same
time, one of them is high or both are high, and
EZH2 high or H3K27me3 high occupies a high ratio as
shown by the relatively low H3K27me3. As shown in
Fig. 2c. SUZ12 and H3K27me3 are low at the same
time, one of them is high, and both of them are high,
and SUZ12 non-high and H3K27me non-high occupies a
high ratio. Finally, Fig. 2d shows that EED1 and
H3K27me3 are low at the same time, one of them is high
and both of them are high. For the same reason, EED1 high
or H3K27me3 high seems to occupy a high percentage.The
expression patterns of EZH2, SUZ12, EED1, and
H3K27me3 were most distinctive; EZH2high and EED1high
were frequently observed in all subtypes. SUZ12high and
H3K27me3high were uniformly infrequent across all
subtypes, whereas H3K27me3high was frequent in Ewing’s
sarcoma. There was no significant difference in the PRC2
expression of each protein with sex (P = 0.965), primary
site of diagnosis (P = 0.512), histologic grade (P = 0.853),
stage at diagnosis (P = 0.205), initial distant metasta-
sis (P = 0.531), surgery (P = 0.259), resection margin
(P = 0.636), and adjuvant treatment (chemotherapy;
P = 0.081, radiotherapy; P = 0.144). The combined
expression of all PRC2 proteins was not significant
for clinicopathologic features.
Survival outcome according to PRC expression
After a median follow-up duration of 33.8 months, 41
patients (39.0%) had died at the time of survival analysis.
The 5-year OS for all patients was 48.7% and the 5-year
OS rates of the subgroups were as follows: 67.4% for
rhabdomyosarcoma, 64.7% for synovial sarcoma, 18.7%
for Ewing sarcoma, 52.1% for osteosarcoma, and 22.0%
for others (mesenchymal chondrosarcoma or epithelioid
sarcoma). In subtype analysis, EZH2high expression was
associated with significantly shortened OS (5-year OS
rate, 78% vs. 41%, P = 0.026, Fig. 3a). The OS was also
significantly poor for SUZ12 high (5-year OS rate, 53% vs.
0%, P = 0.001, Fig. 3b), EED1high (5-year OS rate, 67% vs.
44%, P = 0.279, Fig. 3c), and H3K27me3high (5-year OS
rate, 51% vs. 0%, P = 0.009, Fig. 3d). Ultimately, overex-
pression of PRC2high showed significantly inferior OS
compared to the no expression group (5-year OS rate,
52% vs. 0%, P = 0.009, Fig. 3e). The Cox proportional
hazard model was adjusted for stage, histologic grade,
initial metastasis, surgery, margin status, and EZH2,
SUZ12, H3K27me3, and all PRC2. Initial metastasis
(P = 0.013, HR 3.365, 95% CI 1.295–8.745), SUZ12 ex-
pression (P = 0.020, HR 29.069, 95% CI 1.690–
500.007), and H3K27me3 (P = 0.010, HR 3.743, 95%
CI 1.370–10.228) expression were significantly associ-
ated with a shorter OS (Table 2).
Discussion
We examined the frequency and prognostic impact of
PRC expression in various sarcomas. This is the first study
to evaluate the prognostic impact of PRC expression in
sarcoma subgroups. We found that PRC2 proteins and
H3K27me3 were frequently expressed and that overex-
pression was as an independent prognostic factor for OS.
Accumulating evidence has suggested the controversial
values of PRC expression in solid tumors. Wang et al.
reported that high EZH2 expression was associated with
poor prognosis in colorectal cancer [10], whereas EZH2
expression was associated with relapse-free survival in
another study [11]. Similarly to PRC2, BMI1 was also as-
sociated with good prognosis in breast cancer and poor
Fig. 1 Representative expression of polycomb proteins in sarcoma
(×100). a High-grade expression of EZH2. b Low-grade expression of
EZH2. c, High-grade expression of SUZ12. d, Low-grade expression
of SUZ12. e High-grade expression of EED1. f Low-grade expression
of EED1. g High-grade expression of H3K27me3. h, Low-grade
expression of H3K27me3
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prognosis in colorectal cancer [12, 13]. Clinicopathologic
heterogeneity including primary tumor, pathologic stage,
and chemotherapy or radiotherapy may have contributed
to these controversial results. Furthermore, conclusions
based on one protein marker may lead to inconsistent
results.
In addition to individual markers, combinations of
PRC proteins have been reported by several groups. Co-
expression of EZH2 and BMI1 was found to be a poor
prognostic factor. Coactivation of PRC2 proteins (EZH2,
SUZ12, and EED) were reported to be associated with
inferior OS in NK T cell lymphoma [14]. Esophageal
squamous cell carcinoma, which exhibits high expres-
sion of BMI1 and EZH2, showed poor OS and disease-
free survival. In our study of sarcoma, all PRC proteins
were consistently poor prognostic factors. To obtain
additional prognostic information regarding epigenetic
pathways, we performed multivariate analyses using
combined expression of PRC2 proteins and the
association with histone modification H3K27me3. By
simultaneously examining the protein complex, we
clarified the prognostic value of PRC expression in
sarcoma patients.
Synovial sarcoma has been widely studied to deter-
mine its association with sarcoma-specific genetic aber-
ration. Synovial sarcoma is defined by a characteristic
translocation t(X;18)(p11.2;q11.2), which is observed in
> 95% of cases and results in the fusion of SS18 to the
SSX1, SSX2, or SSX4 genes [15]. Thus, SS18-SSX fusion
leads to disease development by disrupting the epigen-
etic regulation of gene expression. Soulez et al. demon-
strated that the polycomb group proteins RNG1 or BMI
are co-localized with SSX focal staining in synovial
sarcoma [16]. In addition, poorly differentiated synovial
sarcoma showed high expression of EZH2, which was
predictive for distant metastasis [17]. Recently, the SS18-
SSX fusion protein was reported to be associated with
the recruitment of PRC, suggesting polycomb-mediated
epigenetic gene regression as a mechanism of oncogen-
esis in synovial sarcoma cell lines [18].
In a study by Schaefer et al. loss of H3K27 tri-
methylation was shown in 51% (51/100) of malignant
peripheral nerve sheath tumors and in another study by
Prieto-Granada et al., loss of H3K27 tri-methylation was
found in 69% (47/68) of malignant peripheral nerve
sheath tumors [19, 20]. Arjen et al. reports that malig-
nant peripheral nerve sheath tumors with loss of H3K27
tri-methylation showed inferior survival compared to
malignant peripheral nerve sheath tumors with intact
H3K27 tri-methylation [21]. Schaefer et al. demonstrated
increased loss of H3K27 with increasing histological
grade [19]. Combinational effect of genetic aberration,
heterogeneity of primary tumor and treatment modality,
the role of genetic aberration in the progression of sar-
coma can be considered as reasons for these paradoxical
findings in sarcoma.
Fig. 2 High expression rate of polycomb proteins and H3K27me3 according to subtype. a Activation rate for polycomb proteins and H3K27me3.
b Activation rate of EZH2-H3K27me3. c Activation rate of SUZ12-H3K27me3. d Activation rate of EED1-H3K27me3
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Anthracyclines and ifosfamide, either alone or in com-
bination, are the gold standard treatments for advanced
sarcoma [3]. After the failure of conventional first-line
cytotoxic chemotherapy, available treatment options
such as gemcitabine, trabectedin, and pazopanib have
been assessed for the subsequent treatment of sarcoma.
However, these treatments are severely limited because
of their high toxicities and modest survival benefits;
thus, the availability of less toxic agents with novel
mechanisms that can improve progression-free survival
or OS are crucial. Currently, most studies have focused
on the prognostic role of PRC, while the therapeutic role
of PRC has not been widely examined. The initiation of
gene silencing by polycomb activity has been shown
to involve HDAC [22]. The HDAC inhibitor FK228
shows growth inhibitory effects in synovial sarcoma
cell lines and in vivo models [23]. Introduction of
SYT-SSX cDNA enhanced the sensitivity to FK228,
and the growth of synovial sarcoma tumor graft was
markedly inhibited by FK228 treatment. Puppe et al.
reported that BRCA-1-deficient breast cancer, which
overexpress EZH2, was 20-fold more effective com-
pared to BRCA-proficient breast cancer cell lines
when the H3K27me3 selective inhibitor DZNep was
Fig. 3 Polycomb proteins affect overall survival of sarcoma patients based on Kaplan-Meier plots (n = 105). a Overall survival rate according to
EZH2 expression in overall sarcoma. b Overall survival rate according to SUZ12 expression in overall sarcoma. c Overall survival rate according to
EED1 expression in overall sarcoma. d Overall survival rate according to H3K27me3 expression in overall sarcoma. e Overall survival rate according
to all PRC2 expression in overall sarcoma
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used [24]. The S-adenosyl-methionine (SAM)-com-
petitive inhibitors of EZH2, including tazemetostat
(EPZ-6438, E7438) [25], (R)-N-((4-Methoxy-6-methyl-
2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-
(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H–indole-
3-carboxamide (CPI-1205) [26], GSK2816126, are
effective and selective small molecular against EZH2.
Tazemetostat, CPI-1205, and GSK2816126, are cur-
rently performed in the clinical trials in different
cancer types, including lymphomas, kidney tumors,
synovial sarcoma, epitheliod sarcoma, mesothelioma,
advanced solid tumors, and ovarian cancer. Therefore,
PRC are putative therapeutic targets in sarcoma.
The main limitations of our study include its retro-
spective nature and patient selection. Therefore, our
findings should be validated in an independent sar-
coma cohort and the response data to HDAC inhibi-
tors should be examined in future clinical trials.
Higher magnification of IHC staining and normal
tissue comparing may have been better understood,
but in this study it is an important limitation that we
could not prepare it beforehand.
Conclusion
We determined PRC expression in various sarcomas
and demonstrated the independent negative prognos-
tic role of these proteins. Our results suggest the
PRC axis as a promising therapeutic target for the
treatment of sarcoma.
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Table 2 Univariate and multivariate analysis for overall survival
Variables Univariate Multivariate
5-yr OS P-value HR (95% CI) P-value
Sex (Male vs. Female) 49% vs. 48% 0.970
Age (≥20 vs. < 20) 41% vs. 53% 0.690
Stage(I or II vs. III or IV) 60% vs. 36% 0.020
Histologic Grade (Grade 1 or 2 vs. Grade 3) 100% vs. 45% 0.043
Tumor location (Axial vs. Extremity) 42% vs. 52% 0.389
Initial metastasis (Yes vs. No) 16% vs. 55% 0.001 3.365 (1.295–8.745) 0.013
Surgery (Yes vs. No) 50% vs. 0% 0.045
Margin status (R0 vs. R1 or R2) 59% vs. 32% 0.036
EZH2 (non-high vs. high) 78% vs. 41% 0.026
SUZ12 (non-high vs. high) 53% vs. 0% 0.001 29.069 (1.690–500.007) 0.020
EED1 (non-high vs. high) 67% vs. 44% 0.279
H3K27me3 (non-high vs. high) 51% vs. 0% 0.009 3.743 (1.370–10.228) 0.010
All PRC2 (non-high vs. high) 52% vs. 0% 0.009
HR hazard ratio, CI, confidence interval
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